Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB2 | P05107 | 20/20 | 0.81 |
| ▸ | ICAM1 | P05362 | 20/20 | 0.81 |
| ▸ | ITGAL | P20701 | 20/20 | 0.81 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20618445 | 1.00 | ITGB2 (0.81) | ITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL18867790 | 0.93 | ITGB2 (0.80) | ITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL18885221 | 0.93 | ITGB2 (0.80) | ITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL24359993 | 0.92 | ITGB2 (0.71) | ITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL13813644 | 0.91 | ITGB2 (0.78) | ITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL18362309 | 0.90 | ITGB2 (0.67) | ITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL22583607 | 0.90 | ITGB2 (0.67) | ITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL17991463 | 0.90 | ITGB2 (1.00) | ITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL16846644 | 0.90 | ITGB2 (0.85) | ITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL12704679 | 0.90 | ITGB2 (0.85) | ITGB2ICAM1ITGALCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3645529-B1 | PROCESS FOR PREPARING LIFITEGRAST AND INTERMEDIATES THEREOF | SCINOPHARM TAIWAN LTD (TW) | 2023-11-22 | — | — | EP | disclosed |
| WO-2022084739-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | Azura Ophthalmics Ltd. (IL) | 2022-04-28 | — | — | WO | disclosed |
| US-20090155176-A1 | Compositions and methods for treatment of diabetic retinopathy | SARCODE CORPORATION (US) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090155176-A1 | Compositions and methods for treatment of diabetic retinopathy | VCAM1, ITGB1, ICAM1 | ITGB2 11/4885ICAM1 3/4885ITGAL 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.